Skip to contentO
Oncotelic Therapeutics, Inc.
O
OTLCOncotelic Therapeutics, Inc. Q2 2014 · 10-Q
Revenue—
Net Income-$3.93M-$3.93MN/M vs Q2 2013 EPS Diluted-$0.23-$0.23N/M vs Q2 2013 Operating Income-$3,924,000N/M Operating Cash Flowderived-$3,303,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR
ended Jun 30, 2014 · filed Aug 8, 2014 · 39 d after period end